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OBJECTIVE — Urinary liver-type fatty acid-binding protein (u-LFABP) is a marker of tubu-
lointerstitial inﬂammation and has been shown to be increased in patients with type 1 diabetes
and is further increased in patients who progress to micro- and macroalbuminuria. Our aim was
to evaluate u-LFABP as a predictor of progression to micro- and macroalbuminuria in type 1
diabetes.
RESEARCH DESIGN AND METHODS — From an inception cohort of 277 patients,
u-LFABP, adjusted for urinary creatinine (enzyme-linked immunosorbent assay), was measured
in 24-h urine samples from 165 normoalbuminuric patients 9.6  3.5 (mean SD) years after
onset of type 1 diabetes. The outcome measured was development of persistent micro- or
macroalbuminuria or death.
RESULTS — Patients were followed for a median of 18 (range 1–19) years; 39 progressed to
microalbuminuria, 8 of those progressed further to macroalbuminuria, and 24 died. In a Cox
regression model, baseline log u-LFABP levels predicted the development of microalbuminuria,
adjusted for known risk factors (sex, age, A1C, systolic and diastolic blood pressure, albumin
excretionrate,serumcreatinine,andsmoking)(hazardratio[HR]2.3[95%CI1.1–4.6])andlog
u-LFABP predicted mortality (adjusted HR 3.0 [1.3–7.0]). u-LFABP (above versus below the
median) predicted the development of macroalbuminuria (adjusted HR 2.6 [1.2–5.4]). As a
continuous variable, u-LFABP tended to predict macroalbuminuria (HR 1.9, P  0.2), but
numbers were small.
CONCLUSIONS — High levels of the tubular inﬂammation marker u-LFABP predict the
initiation and progression to diabetic nephropathy and all-cause mortality, independent of
urinary albumin excretion rate and other established risk factors.
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D
uring the past few decades the pre-
vention and treatment of late com-
plications in diabetes have
improved dramatically. The focus on pre-
vention of late diabetes complications has
changed and now involves tight glycemic
control, reducing blood pressure, and
lipid lowering (1), but, despite these ef-
forts, diabetic patients still develop
complications.
Approximately 30–40% of all pa-
tients with diabetes develop diabetic ne-
phropathy (1), and this is the leading
cause of end-stage renal disease in the
Western world. In addition, diabetic ne-
phropathy is associated with a higher risk
of other complications (cardiovascular
disease, neuropathy, and retinopathy)
andwithanincreaseinall-causemortality
(2).
It is known that tubulointerstitial
damage plays an important role in dia-
betic nephropathy (3). Therefore, it
would potentially be beneﬁcial if albu-
minuria, as a marker of glomerular dam-
age, could be supplemented by a marker
oftubulardamagetoprovideamorecom-
plete status of the kidney injury. This
couldhelpusﬁrsttomoreaccuratelypre-
dict the patients at risk of developing di-
abetic nephropathy and second to
provide a better and possibly different
treatment for diabetic nephropathy.
Liver-type fatty acid-binding protein
(LFABP) is an intracellular carrier protein
that is expressed in the proximal tubules
in the human kidney and the liver (4). It
has been demonstrated to be a marker of
tubular damage (5).
Previously we have, in a cross-
sectional setting, shown that urinary (u)-
LFABP is increased in diabetic patients,
even before they develop signs of glomer-
ular damage, microalbuminuria or mac-
roalbuminuria (6). This indicates that
tubulardamageispresentatanearlystage
of diabetic kidney damage, even before
thedevelopmentofmicroalbuminuria.u-
LFABP has, to our knowledge, not yet
been studied in a prospective cohort
study in type 1 diabetic patients.
To extend our previous cross-
sectional ﬁndings we have evaluated the
prognosticvalueofu-LFABPinaprospec-
tive study of type 1 diabetic patients who
were still in a normoalbuminuric state.
We have thereby been able to investigate
whether u-LFABP contributes further to
the established predictors for develop-
ment of microalbuminuria or macroalbu-
minuria and the risk of death.
RESEARCH DESIGN AND
METHODS— We recruited an incep-
tion cohort of 277 patients from the out-
patient clinic at Steno Diabetes Center
from1979to1984foraprospectivestudy
of risk factors for development of compli-
cations. Figure 1 shows the design of the
study and a ﬂow chart. The patients had
newly diagnosed type 1 diabetes. They
were treated according to guidelines de-
scribed earlier (7) and were followed
yearly with blood and urine samples (8).
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1990 were lost, so in our analyses we in-
cluded urine samples from 1990 and on-
ward. Urine samples were available for
204 patients and of these 165 patients
were normoalbuminuric. In 2008 we de-
cided to analyze these urine samples for
u-LFABP. u-LFABP was measured in the
ﬁrst urine sample available after 1990,
9.63.5years(meanSD)afteronsetof
type 1 diabetes, and this was considered
baseline in the present study (Fig. 1).
Hereafter, the patients were followed re-
gardingendpointsforamedian(range)of
18(1–19)years.Theprimaryoutcomesin
our study were time to development of
microalbuminuria or macroalbuminuria
ordeathandwereevaluatedfromthetime
of the patients’ ﬁrst urine sample after
1990 and until 2008 or the last available
urinesampleinpatientslosttofollow-up.
Vital status was assessed in 2008 in the
NationalRegistryforallpatients.Allclin-
ical baseline data were calculated as a
mean of observations from the baseline
year for each patient.
As far as possible, urinary albumin
excretionper24hwasmeasuredyearlyin
each patient. Persistent microalbumin-
uria and persistent macroalbuminuria
were deﬁned as a urinary albumin excre-
tionrate(UAER)between30and300and
300 mg/24 h, respectively, in at least
two of three consecutive samples. All
urine samples were collected as 24-h
samples.
Arterialbloodpressurewasmeasured
atleastonceperyearwithastandardmer-
cury sphygmomanometer and was per-
formed with the patient in a seated
position after 10 min of rest. Smoking
historywasdeterminedviaquestionnaire,
and patients were classiﬁed as smokers if
they were smoking 1 cigarette per day.
Urine samples were stored at 20°C
until u-LFABP analysis in 2009. u-LFABP
was measured in a two-step sandwich en-
zyme-linked immunosorbent assay (9)
and adjusted for u-creatinine. The inter-
and intra-assay variations was 6.8 and
8.2%, respectively.
All patients provided informed con-
sent for the participation in the study.
Statistical analysis
Data are means  SD for the normally
distributed variables. Variables with
skewed distribution are given as geomet-
ric means (95% CI). Cumulative inci-
dences of microalbuminuria and
macroalbuminuria were calculated using
Coxregressionanalyses.InTable1differ-
ences between groups are analyzed using
ANOVA.
ACoxmodelforeachofthethreeend
points (development of microalbumin-
uria, development of macroalbuminuria,
ordeath)wasanalyzedinall165patients.
Microalbuminuria was most frequent but
was a surrogate end point, and thus we
analyzed the development of macroalbu-
minuria separately. If a patient was cate-
gorized as “microalbuminuric” or
“macroalbuminuric” (two of three sam-
ples), heorshewould not be recategorized
if they later regressed in albuminuria. Pa-
tients were followed to 2008 or were cen-
sored at time of death. Patients who were
lost to follow-up were counted in the
analyses using the results of their last
available urine sample. By using the Na-
Figure 1—Design of the study.
Nielsen and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 6, JUNE 2010 1321tional Register, vital status was available
for all patients by the end of 2008.
A Cox regression model was used to
analyze u-LFABP as an explanatory vari-
able for the development of microalbu-
minuria and macroalbuminuria or death.
Subsequently the model was adjusted for
knownriskfactors:sex,age,A1C,systolic
and diastolic blood pressure, UAER, se-
rum creatinine, and smoking. Schoenfeld
residuals were plotted against time to test
for violation of the proportional hazards
assumption, and linearity of the log haz-
ard function was assessed by plotting the
Martingale residuals against the covari-
ates. We looked for interaction between
u-LFABP and sex, A1C, or urinary albu-
min-to-creatinine ratio but found no evi-
dence of interaction. Although the
number of variables can be discussed, we
found the model to work well for mi-
croalbuminuria with the listed and usu-
allyappliedcovariates.Modelswithfewer
variables gave very similar hazard ratios
(HRs) for predicting microalbuminuria;
subsequently we applied the same model
to the other end points.
u-LFABP is reported as a categorical
variable in Fig. 2 for the presentation of a
Kaplan-Meierplot.Receiveroperatingchar-
Table 1—Baseline characteristics of the 165 normoalbuminuric type 1 diabetic patients who had their u-LFABP measured in 1990 or later,
divided into groups according to their later development of microalbuminuria or macroalbuminuria or persistent normoalbuminuria
Persistent
normoalbuminuria
Only
microalbuminuria Macroalbuminuria Progressors P value*
n (male/female) 62/64 22/9 6/2 28/11 0.05
Age (years) 37  12 41.7  2.4 43  94 1  15 0.18
Diabetes duration (years) 8.6  3.4 8.4  1.8 12.1  4.5 9.0  2.8 0.05
Systolic blood pressure (mmHg) 122  15 128  16 138  20 130  17 0.02
Diastolic blood pressure (mmHg) 77  87 9  98 6  14 81  10 0.01
UAER (mg/24 h) 8 (7–9) 11 (8–14) 12 (7–20) 11 (9–14) 0.02
A1C (%) 8.2  1.1 8.6  1.7 9.1  0.9 8.7  1.6 0.02
Serum creatinine (mol/l) 72  11 69  12 70  13 69  12 0.48
u-LFABP/creatinine (pg/ml)/(mg/dl) 9.6 (7.8–11.8) 13.4 (8.4–21.3) 12.6 (8.4–21) 13.2 (8.8–19.9) 0.35
Data are means  SD or geometric means (95% CI). The microalbuminuria group does not include patients who later developed macroalbuminuria. Progressors
include those who progressed to microalbuminuria and macroalbuminuria. *Overall difference between normoalbuminuric, microalbuminuric, and macroalbu-
minuric groups compared by ANOVA.
Figure2—Kaplan-Meierplot:elevatedbaselineu-LFABPlevelsin165normoalbuminurictype1diabeticpatientspredictprogressiontomicroalbu-
minuria. Quartiles with limits: u-LFABP/creatinine: 4.7, 10.9 and 21.3 (pg/ml)/(mg/dl). P  0.02 for overall difference.
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(SPSS,Chicago,IL),assumingnonparamet-
ricdistributionofparametersforSEofarea.
Statistical signiﬁcance was assumed
for P 	 0.05. Data were analyzed using
SPSS 15.0.
RESULTS— At baseline, 165 patients
of the 204 patients followed since 1979–
1984 were persistently normoalbumin-
uric, and our later analyses and reported
dataarebasedonthesepatients(seeFig.1
forﬂowchart).MeanSDageatbaseline
was3812.6years.Diabetesdurationat
baselinewas9.63.5years.Thepatients
were followed for a median (range) of 18
(1–19) years. Successful follow-up until
the end point or year 2008 was available
in90.3%ofallpatients.Duringfollow-up
to 2008, 39 patients had developed per-
sistent microalbuminuria, and of these 8
patients progressed further to persistent
macroalbuminuria. During follow-up, 24
patients died. The cumulative incidence
of microalbuminuria was mean 27%
(95% CI 20–35), of macroalbuminuria
was 6% (2–10), and of death was 17%
(11–23).
Baseline characteristics of the pa-
tients, when divided into groups accord-
ing to the later development of
microalbuminuria and macroalbumin-
uria or persistent normoalbuminuria, can
be seen in Table 1. Patients who later de-
velopedmicroalbuminuriaormacroalbu-
minuria had higher systolic and diastolic
bloodpressurethanthepatientswithper-
sistent normoalbuminuria (P 	 0.05).
A1Cwasprogressivelygreaterinthemac-
roalbuminuric and microalbuminuric
groups than in the normoalbuminuric
group (P  0.02). UAER was also in-
creased in the patients later developing
microalbuminuria or macroalbuminuria;
however, there were no signiﬁcant differ-
ence between the groups. As demon-
stratedinTable1,u-LFABPwasincreased
in the microalbuminuric and macroalbu-
minuric patients compared with the pa-
tients with persistent normoalbuminuria;
however, this result was not statistically
signiﬁcant (P  0.17 and P  0.52).
In a Cox regression model (Table 2),
baselinelogu-LFABPlevelspredictedmi-
croalbuminuriawhenadjustedforknown
risk factors (age, sex, A1C, systolic and
diastolic blood pressure, UAER, serum
creatinine,andsmoking)withaHRof2.3
(95% CI 1.1–4.6). When u-LFABP was
analyzed as a predictor of microalbumin-
uria using receiver operating curve analy-
sis, we found that with addition of
u-LFABP to the known risk factors (age,
sex, A1C, systolic and diastolic blood
pressure, UAER, serum creatinine, and
smoking), the area under the curve in-
creased only slightly from 0.80 (0.71–
0.89) to 0.81 (0.72–0.91).
As demonstrated in a Kaplan-Meier
plot in Fig. 2, u-LFABP divided into quar-
tiles predicts the development of mi-
croalbuminuria (P  0.024). The HR from
theﬁrsttofourthquartileis5.8(P0.004).
As a continuous variable, u-LFABP
tended to predict the development of
macroalbuminuria (HR 1.9), but this re-
sult was not statistically signiﬁcant (P 
0.2), most likely because numbers were
small (n  8). When analyzed as a cate-
gorical variable u-LFABP [above versus
below the median  10.9 (pg/ml)/(mg/dl
creatinine)]predictedthedevelopmentof
macroalbuminuria (HR 2.6 [95% CI 1.2–
5.4]; adjusted for risk factors, see above).
During follow-up, 24 patients died.
As a continuous variable, high levels of
u-LFABP were associated with a signiﬁ-
cant increased risk of mortality (adjusted
HR 3.0 [95% CI 1.3–7.0].
CONCLUSIONS— In our study u-
LFABP predicted the future development
of microalbuminuria and death in nor-
moalbuminuric type 1 diabetic patients
from an inception cohort study. The pa-
tients were followed for a median of 18
years, and the cumulative incidence of
microalbuminuria and macroalbumin-
uria was mean 27% (95% CI 20–35) and
6% (2–10), respectively.
Previously, we demonstrated that u-
LFABPisincreasedalreadyinnormoalbu-
minuric type 1 diabetic patients,
indicating a “tubular phase” in the patho-
genesis to diabetic kidney damage (6).
However, this was done in a cross-
sectional study, which in its design has
somelimitations,andthusnothingcanbe
concluded on the time perspective be-
tween elevated u-LFABP and progression
to microalbuminuria and macroalbumin-
uria.Withthedesignofthepresentstudy,
we have been able to demonstrate that
high levels of u-LFABP are evident even
beforethedevelopmentofmicroalbumin-
uria and hence at an early state where the
glomerular damage is not detectable (al-
bumin excretion rate not elevated), but
where the tubules are affected (elevated
u-LFABP). In Table 2 it is seen that ele-
vated urinary albumin excretion in the
normal range is also a strong predictor of
progression to microalbuminuria. How-
ever, our aim was to supplement urinary
albumin as a measure rather than replace
it. If patients are followed over time, it is
possible that changes in the markers
within the normal range could add pre-
dictive value; however, we aimed to im-
prove prediction of prognosis from a
single point in time.
In an abstract presented at the Amer-
ican Society of Nephrology meeting in
2009 Kamijo et al. (10) reported that u-
LFABP predicts a decrease in estimated
glomerular ﬁltration rate in type 2 dia-
betic patients with diabetic nephropathy.
This ﬁnding supports our results and in-
dicates that u-LFABP is a promising
marker in not only type 1 but also type 2
diabetic patients. In a study of nondia-
betic patients with chronic kidney dis-
ease, similar results were found: kidney
function in patients with u-LFABP levels
above the median deteriorated faster than
that in patients with u-LFABP below the
median during 1 year of follow-up (11).
Tamm-Horsfall protein, another marker
of tubular damage, is produced in the
thick ascending limb of Henle. Tamm-
Horsfallproteinhasbeenfoundtobepre-
dictive of cardiovascular death and
uremia in type 1 but not type 2 diabetic
patients (12). This ﬁnding again supports
Table 2—Cox regression: u-LFABP predicts the development of microalbuminuria when ad-
justed for known risk factors
Odds ratio (95% CI) P value
Sex (male) 4.19 (1.62–10.87) 0.003
Age (year) 1.02 (0.99–1.05) 0.274
A1C (%) 2.00 (1.36–2.95) 	0.001
Systolic blood pressure (mmHg) 1.03 (0.995–1.06) 0.100
Diastolic blood pressure (mmHg) 0.99 (0.94–1.04) 0.758
Log (urinary albumin mg/24 h) 12.36 (2.58–59.32) 0.002
Log (u-LFABP ng/ml/urinary creatinine) 2.28 (1.14–4.58) 0.021
Theanalysesincludessex,age,A1C,systolicanddiastolicbloodpressure,UAER,u-LFABP,serumcreatinine
(not shown), and smoking (not shown).
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be added to albuminuria in the risk as-
sessment of the development of diabetic
nephropathy.
In the present study, we found that
u-LFABP predicted death. It is not possi-
ble to deﬁne the causality, but it is most
likely that the effect of u-LFABP is medi-
atedthroughthedevelopmentofelevated
urinary albumin excretion. We found that
patientswhodiedhadasigniﬁcantlyhigher
incidence of microalbuminuria or mac-
roalbuminuria than patients who survived
during follow-up (41 vs. 21%, P  0.027).
By studying renal biopsy specimens
with immunohistochemical staining, it
hasbeenshownthatu-LFABPexcretionis
closely associated with structural and
functional tubular kidney damage (13).
This ﬁnding was conﬁrmed in patients
with chronic kidney disease including
minimal change nephrotic syndrome, ne-
phrosclerosis, lupus nephritis, and dia-
betic nephropathy (14). In a recent
experimental study in transgenic mice, it
has been shown that u-LFABP accurately
reﬂects the degree of tubulointerstitial
damage and is dynamic as a measure; it
increases and decreases, reﬂecting dam-
age and repair of the tubular cells (15). In
accordance with these results, we previ-
ously reported that u-LFABP excretion is
reduced when type 1 diabetic patients
with diabetic nephropathy are treated with
renoprotective treatment such as the ACE
inhibitorlisinopril(6).Thisﬁndingleadsto
speculations on u-LFABP as a monitor of
renoprotective treatment; however, more
studies are needed to conﬁrm this.
Our results show that high levels of
u-LFABP predict the development of mi-
croalbuminuria and diabetic nephropa-
thy.However,thisdoesnotdeterminethe
mechanism or the role of LFABP: it has
been hypothesized that LFABP is a pro-
tective protein (16), but previous studies
have, to our knowledge, not been able to
conﬁrm this hypothesis (17). u-LFABP as
a continuous variable did not predict
macroalbuminuria,butitdidasacategor-
ical variable. Because of the low number
of events (n  8), the analysis has to be
interpreted with caution, but it is in line
with the prediction of microalbuminuria.
The present study has some limita-
tions. The patients only had their u-
LFABP measured in one 24-h urine
sample, and the urine samples were
stored at 20°C for 18 years before
analyses. Another limitation is the loss of
urine samples before 1990 (Fig. 1). How-
ever, this most likely results in a underesti-
mation of the predictive power of u-LFABP
aspatientsmostsusceptibletorenaldisease,
probably having the most tubular damage,
already had developed microalbuminuria
or macroalbuminuria and were excluded.
The strengths of our study are that all pa-
tients were followed for vital status and
90% were followed to 2008 or the devel-
opment of a renal end point.
In summary, we demonstrate that u-
LFABP is elevated at an early stage, even
before any clinical signs of glomerular
damagearedetectable,conﬁrmingthehy-
pothesis of a “tubular phase” in the devel-
opment of diabetic nephropathy.
u-LFABP is seen to be independent pre-
dictor of microalbuminuria and death.
Thus, u-LFABP may be used as an indica-
tor of tubular damage early in the course
of diabetes and therefore may ﬁnd a place
as a new tool in the prediction of diabetic
nephropathy. However, further studies
are needed for conﬁrmation.
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